List of Excipients in Branded Drug ORIAHNN

✉ Email this page to a colleague

Last updated: May 12, 2026

ecutive summary: ORIAHNN (elagolix/estradiol/norethindrone acetate; tablets) is built on a tightly specified multi-compound fixed-dose formulation with explicit dosing ratios across 3 regimens. Commercial opportunity from an “excipient strategy” perspective is concentrated in (1) patient-centric film-coating and tablet robustness to protect low-dose actives from moisture/processing stress, (2) compatible dissolution and in vivo exposure for the two Elagolix salt components plus steroid actives, and (3) manufacturing and regulatory pathways that reduce formulation-IP friction for challengers. For entrants, the key risk is that excipient substitutions can trigger bioequivalence failure, comparator dissolution differences, or discovery of formulation-specific IP claims; for the branded holder, the key value is using excipient control to preserve the fixed-dose performance envelope that supports exclusivity and discourages “design-around” generic filings.

ORIAHNN excipient strategy and formulation IP: What inactive ingredients enable the fixed-dose tablet performance?

ORIAHNN is a three-tablet-regimen fixed-dose combination using elagolix (GnRH antagonist) co-administered with estradiol and norethindrone acetate. From a commercial and development standpoint, the formulation is best understood as an engineered dissolution and stability system with excipient roles that typically fall into five categories: (1) binder/filler matrix, (2) disintegrant, (3) film coat and moisture barrier, (4) lubricant/processing aids, and (5) stabilizers and compatibility controls for steroid and GnRH antagonist chemistry.

Why excipients matter in ORIAHNN’s combination tablet

Fixed-dose combinations are where excipient strategy becomes commercially material. Small changes in:

tablet coat permeability,
disintegrant identity or particle size,
lubricant level (e.g., magnesium stearate grade and lubrication time),
binder viscosity or polymorph-driving excipient selection, can shift dissolution rate of one component while leaving others less affected. In a triple-component regimen, even if each component is individually “released,” the combined pharmacokinetic profile must remain within bioequivalence tolerances.

Excipients as the controllable lever for product “performance envelope”

For ORIAHNN, the performance envelope is the combination of:

manufacturing robustness (hardness, friability, coat integrity),
dissolution and exposure consistency across lots,
shelf-life under real distribution conditions,
stability of both steroid actives and elagolix with respect to moisture, oxygen, and light.

An excipient strategy for competitive products is therefore less about “finding any excipient” and more about replicating the tablet’s release and stability behavior.

Practical commercial implication: entrants that attempt excipient design-around without matching the release kinetics and stability behavior face higher risk of bioequivalence failure or litigation discovery around whether “non-obvious” substitutions preserve the protected formulation characteristics.

What patents protect ORIAHNN excipients and tablet formulations?

An excipient strategy is only actionable if it aligns with the patent estate. ORIAHNN’s patent landscape generally covers:

composition of matter for the active combination (and sometimes specific salts, ratios, or crystal forms),
formulation compositions and related ranges of excipients,
manufacturing methods (granulation, compression, coating steps),
unit dosage regimen claims that map to the three regimen tablets.

What to expect from formulation patent coverage in fixed-dose combinations

In typical combination tablet estates, formulation patents often claim combinations of:

disintegrants and binders,
specific film-coat compositions (polymer, plasticizer, pigments),
moisture/chemical stabilizer systems,
particle size or processing parameters tied to release.

Even when a generic can avoid an exact ingredient list, patents can still capture broader functional equivalence such as:

claimed excipient classes with minimum concentrations,
specific ratios among excipients,
defined dissolution targets with explicit manufacturing steps.

For commercial strategy, the highest-value diligence is claim-by-claim mapping of excipient-related limitations to design-around possibilities. Without that mapping, excipient substitution becomes a litigation and regulatory risk rather than a development shortcut.

How many formulation and method-of-manufacture patents cover ORIAHNN tablets?

This cannot be answered completely from the information provided. A quantified count requires the specific Orange Book listings, patent numbers, and assignees tied to ORIAHNN’s NDA/BLA records, plus cross-checking with court dockets for claim sets that include excipient and manufacturing limitations.

When does ORIAHNN lose exclusivity for formulation-based competition?

This cannot be calculated accurately from the information provided. Determining loss of exclusivity requires:

the NDA exclusivity and patent expiration dates,
any pediatric exclusivity extensions,
the presence and end dates of regulatory exclusivities (such as 5-year and 7-year periods where applicable),
timing of any settlement-based “competing generic” triggers tied to Orange Book listed patents.

What is the Orange Book status of ORIAHNN patents that could constrain excipient substitutions?

This cannot be stated accurately from the information provided. Orange Book status needs:

exact listed patents for the NDA,
their expiration dates,
whether they are formulation, method-of-use, or manufacturing patents,
whether there are multiple patents per dosage form and strength.

Can a generic or biosimilar use different excipients for ORIAHNN and still get approval?

ORIAHNN is a small-molecule fixed-dose oral product, so the competition risk is with chemically identical generics (ANDA) rather than biosimilars. The pathway is typically:

ANDA with bioequivalence (unless another waiver applies),
reliance on reference listed drug (RLD) specifications and dissolution targets.

Where excipient differences create ANDA risk

Common failure points when excipients are changed in fixed-dose combinations include:

dissolution profile mismatch (especially with film-coated tablets),
instability-driven lot-to-lot variability,
altered disintegration time leading to differential exposure,
reduced robustness under manufacturing stress that increases impurity formation.

High-leverage excipient strategy for challengers

A challenger’s most efficient excipient approach is typically:

match the RLD’s release-critical excipient functions,
preserve coating permeability and disintegration behavior,
match lubricant level and lubrication time to avoid hydrophobicity-driven dissolution suppression,
control moisture and oxygen sensitivity using a coat and packaging strategy aligned with the RLD stability model.

Commercial implication: excipient substitution is not free. It can force expensive bridging studies, extend timeline, and increase Paragraph IV litigation exposure if formulation IP is asserted.

What excipient changes are most likely to be considered “design-around” for ORIAHNN formulation patents?

This cannot be determined precisely without the text of the ORIAHNN formulation claims and the RLD excipient list. In general, for tablet formulation patents, design-around attempts that have historically attracted scrutiny include:

substituting disintegrants (e.g., crospovidone to croscarmellose),
substituting binders (PVP to HPMC systems),
altering film-coat polymers/plasticizers to change coat permeability,
changing stabilizers or antioxidants where claimed.

Risk driver: courts and regulators look for whether the alternative still meets the claimed functional or compositional limitations. Without claim text, this cannot be translated into a safe “allowed substitution list.”

What patient adherence or dosing-regimen design issues affect formulation and excipient choices for ORIAHNN?

ORIAHNN uses multiple regimen tablets across a course of therapy. That means formulation differences must support:

accurate regimen identification,
consistent release behavior across the course,
physical robustness to reduce dose-related administration errors.

Commercial impact of regimen presentation on excipient choices

Even if actives are correct, dosing failures often arise from:

tablet fragility during packaging and shipping,
film coat cracking and increased moisture uptake,
color/appearance cues that depend on pigments and coat composition.

Excipient strategies that stabilize coating integrity can reduce returns and improve clinician and patient confidence, which affects commercial performance.

What manufacturing and scale-up constraints do excipients impose for ORIAHNN tablets?

Fixed-dose combinations at commercial scale require excipients that:

support predictable granulation and compression,
provide consistent dissolution,
are available at the needed grades and particle size distributions,
maintain consistent moisture content through blending, drying, and coating.

Scale-up points that can force rework

Where excipients are sensitive, scale-up can drive:

changes in bulk density and flow affecting die fill,
differences in binder hydration leading to hardness shifts,
lubricant lot-to-lot variability changing dissolution.

Commercial opportunity for excipient supply chain differentiation

Companies can gain leverage through:

validated alternative excipient qualification packages,
co-development with contract manufacturers to create robust design spaces,
using coating systems that reduce coating defects and moisture sensitivity risk.

Which companies are best positioned to exploit excipient-based formulation differentiation against ORIAHNN?

This cannot be answered without a current competitive mapping of ANDA filers, Paragraph IV notice recipients, court filings, and Orange Book challenge activity tied to ORIAHNN’s listed patents.

What generic entry risks exist for ORIAHNN based on excipient and formulation vulnerabilities?

This cannot be quantified without knowing:

the exact ORIAHNN RLD excipient list and coat composition,
the formulation patent claim scope,
the ANDA history for ORIAHNN (if any).

In general terms, the highest risks for challengers in triple-therapy fixed-dose tablets are:

inability to match dissolution and in vivo exposure due to excipient-driven release changes,
instability-driven impurity increases that can block approval,
formulation-specific IP asserted through Paragraph IV litigation.

Commercial opportunities: Where can an “excipient strategy” create value around ORIAHNN?

Even without claiming to replace ORIAHNN directly, excipient-centered opportunities exist across four business tracks.

1) Portfolio defense and lifecycle management for the branded holder

A branded holder can:

refine coating and stability controls to reduce degradation and improve shelf life,
validate alternative excipient grades to secure supply without performance drift,
optimize tablet hardness and disintegration to reduce rejects.

Value driver: reduces manufacturing downtime and protects net sales by limiting supply disruptions.

2) Differentiated generics and authorized generics

If a licensed generic can negotiate a pathway that reduces litigation risk, excipient control becomes a lever for:

achieving robust bioequivalence with fewer bridging iterations,
improving manufacturability and reducing per-unit cost.

Value driver: lower COGS without performance compromise.

3) Contract development and scale-up services for other triple-combination regimens

ORIAHNN’s model is a template for future combinations in endometriosis and women’s health. A developed excipient and manufacturing playbook can be monetized via:

platform formulation work,
tech transfer packages,
validated design spaces.

Value driver: recurring revenue in CMC services.

4) Supply chain and regulatory resilience

Excipient risk management can generate commercial advantage by:

pre-qualifying alternative excipient sources,
maintaining release-critical specs for coating and disintegration.

Value driver: continuity and reduced batch failure rates.

Key Takeaways

ORIAHNN is a fixed-dose triple-combination where excipients control dissolution, moisture stability, and coating integrity across regimen tablets.
The commercial value of excipient strategy is highest in maintaining a narrow performance envelope that protects bioequivalence outcomes and reduces manufacturing defects.
For challengers, excipient substitutions are a high-risk design variable unless aligned to formulation-specific patent claim scope and dissolution/stability targets.
The most actionable opportunities center on lifecycle stability, manufacturing robustness, and supply-chain resilient excipient qualification rather than superficial ingredient swaps.

FAQs

How do film-coat excipients influence dissolution of fixed-dose triple-combination tablets like ORIAHNN?
What excipient and processing parameters most commonly fail bioequivalence for combination tablet ANDAs?
How does excipient moisture-barrier selection affect tablet shelf-life under distribution humidity profiles?
What CMC documentation best supports design space justification when substituting excipient grades for marketed combination tablets?
How do excipient-related formulation claims typically appear in patent litigation for fixed-dose tablet products?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
U.S. Food and Drug Administration. ANDA Bioequivalence Guidance documents and related regulations. FDA.

More… ↓

⤷ Start Trial